Dylan M. Johnson
University of Louisville
11 Papers
8 Citations
Dylan M. Johnson is an academic researcher from University of Louisville. The author has contributed to research in topics: Biology & Virus. The author has an hindex of 4, co-authored 5 publications.
Chat about Author
Papers
Novel DNA-launched Venezuelan equine encephalitis virus vaccine with rearranged genome.
Irina Tretyakova,Alexander Tibbens,Jenny D. Jokinen,Dylan M. Johnson,Igor S. Lukashevich,Peter Pushko +5 more
TL;DR: It is concluded that V4020 vaccine has safety advantage over TC83, while provides equivalent protection in a mouse VEEV challenge model.
25
Attenuated Replication of Lassa Virus Vaccine Candidate ML29 in STAT-1-/- Mice
TL;DR: It is demonstrated that ML29 was more attenuated than MOPV in STAT1-/- mice, a small animal model of human LF and its sequelae, and formulation of ML29 with IPs will improve the breadth of the host's immune responses and further contribute to development of a pan-LASV vaccine with full coverage meeting the WHO requirements.
18
Advanced Safety and Genetic Stability in Mice of a Novel DNA-Launched Venezuelan Equine Encephalitis Virus Vaccine with Rearranged Structural Genes.
Dylan M. Johnson,Kevin J. Sokoloski,Jenny D. Jokinen,Tia L. Pfeffer,Yong Kyu Chu,Robert S. Adcock,Donghoon Chung,Irina Tretyakova,Peter Pushko,Igor S. Lukashevich +9 more
TL;DR: Evidence is provided for the improved safety and genetic stability of the experimental V4020 VEEV vaccine in a murine model with less severe clinical manifestations and a lower viral load during five serial passages in the brain.
15
Lassa Virus Vaccine Candidate ML29 Generates Truncated Viral RNAs Which Contribute to Interfering Activity and Attenuation.
TL;DR: In this paper, the Lassa fever (LF) vaccine candidate ML29, a reassortant that carries the nucleoprotein (NP) and glycoprotein (GP) dominant antigens of the pathogenic lassa virus (LASV) together with the L polymerase and Z matrix protein of the nonpathogenic genetically related Mopeia virus (MOPV), are readily detected following infection at low multiplicity of infection (MOI) or in persistently infected cells originally infected at high MOI.
15
Evaluation of molnupiravir (EIDD-2801) efficacy against SARS-CoV-2 in the rhesus macaque model
Dylan M. Johnson,Trevor Brasel,Shane Massey,Tania Garron,Michael Grimes,Jeanon N. Smith,Maricela Torres,Shannon M. Wallace,Alejandro G. Villasante-Tezanos,David W.C. Beasley,Jason E. Comer +10 more
TL;DR: In this article , the authors evaluated molnupiravir for efficacy as an oral treatment in the rhesus macaque model of SARS-CoV-2 infection.
13